143558-00-3 | Rocuronium

Chemical type

• Non-depolarizing muscle relaxant (NDMR)

^[1]

• Non-depolarizing neuromuscular blocker (aminosteroid)

^[2]

Key properties

• Dose-dependent inhibitor of twitch tensions in skeletal muscle
• IC₅₀ increased by burn injuries (e.g., from ~566 µg/kg in sham to ~795 µg/kg in burned legs)
• Resistance induced by burns reversed by HDAC4 inhibition
• Administered intravenously in incremental doses (100-3200 µg/kg)

^[1]

• Blocks acetylcholine at neuromuscular junction
• Intermediate duration of action

^[2]

• Muscle relaxant for anesthesia in burn-injured patients to facilitate intubation and surgery
• Assessed for potency in tension tests post-burn injury
• Tool to study NDMR resistance mechanisms in skeletal muscle

^[1]

• Muscle relaxation for intubation (0.6 mg/kg intravenous) during anesthesia induction

^[2]

Classification by use

• Chemicals used as neuromuscular blocking agents
• Chemicals used in anesthesiology
• Chemicals used in burn injury pharmacology research

^[1]

• Neuromuscular blocking agents

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Trichostatin A reverses rocuronium resistance in burn-injured rats, Burns, Volume 51, Issue 2, March 2025, 107351
2. [Cite:2] Lidocaine mitigates cognitive decline in elderly patients after video-assisted thoracoscopic surgery: A double-blind randomized controlled clinical trial, Brain Disorders, Volume 21, March 2026, 100308